Publications by authors named "F Megraud"
Introduction: To evaluate the prescription patterns, effectiveness, and safety of adding probiotics to Helicobacter pylori eradication therapy, in Europe.
Methods: International, prospective, noninterventional registry of the clinical practice of the European gastroenterologists. Data were collected and quality reviewed until March 2021 at AEG-REDCap.
International consensus statement on microbiome testing in clinical practice.
Lancet Gastroenterol Hepatol
February 2025
There is growing interest in the potential exploitation of the gut microbiome as a diagnostic tool in medicine, but evidence supporting its clinical usefulness is scarce. An increasing number of commercial providers offer direct-to-consumer microbiome diagnostic tests without any consensus on their regulation or any proven value in clinical practice, which could result in considerable waste of individual and health-care resources and potential drawbacks in the clinical management of patients. We convened an international multidisciplinary expert panel to standardise best practices of microbiome testing for clinical implementation, including recommendations on general principles and minimum requirements for their provision, indications, pre-testing protocols, method of analyses, reporting of results, and potential clinical value.
View Article and Find Full Text PDFArticle Synopsis
- The efficacy of vonoprazan-based therapies for treating infection was similar across various demographic factors like age, sex, race, and ethnicity.
- Both dual and triple therapies using vonoprazan showed consistent results compared to lansoprazole-based triple therapy.
- Factors like BMI, alcohol intake, smoking status, and adherence to the study drug did not significantly affect treatment outcomes.
Article Synopsis
- Bismuth quadruple therapies (BQTs) have been effective in treating Helicobacter pylori infections in Europe, particularly in the face of antibiotic resistance, with notable use increasing from 8.6% in 2013 to 39% in 2021.
- An analysis of data from nearly 50,000 patients indicated that the single-capsule BQT was the most common regimen and achieved over 90% effectiveness with certain combinations.
- Key factors that improved treatment success included adherence to the regimen, use of high-dose proton pump inhibitors, and implementing the therapy as a first-line treatment.
Background: Evolving epidemiological data and increasing antibiotic resistance mandate an update of the European and North American Societies of Pediatric Gastroenterology, Hepatology and Nutrition guidelines.
Methods: Certainty of evidence and strength of recommendations were rated by experts according to the Grading of Recommendation Assessment, Development, and Evaluation approach. PICO (patient population, intervention, comparator, and outcome) questions were developed and voted on by the group.